Equities analysts expect Agenus Inc. (NASDAQ:AGEN) to post $6.49 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Agenus’ earnings, with the lowest sales estimate coming in at $6.00 million and the highest estimate coming in at $6.98 million. Agenus posted sales of $6.59 million in the same quarter last year, which suggests a negative year over year growth rate of 1.5%. The company is scheduled to report its next quarterly earnings report on Thursday, July 27th.

On average, analysts expect that Agenus will report full year sales of $6.49 million for the current financial year, with estimates ranging from $48.26 million to $66.60 million. For the next fiscal year, analysts expect that the firm will report sales of $32.85 million per share, with estimates ranging from $30.09 million to $35.60 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Agenus.

Agenus (NASDAQ:AGEN) last issued its earnings results on Thursday, May 4th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.14. The company had revenue of $26.96 million during the quarter, compared to the consensus estimate of $5.22 million. Agenus had a negative net margin of 257.79% and a negative return on equity of 37,577.49%.

A number of research firms have weighed in on AGEN. HC Wainwright set a $5.00 price objective on shares of Agenus and gave the company a “hold” rating in a report on Saturday, May 6th. ValuEngine raised shares of Agenus from a “strong sell” rating to a “sell” rating in a report on Monday. BidaskClub raised shares of Agenus from a “hold” rating to a “buy” rating in a report on Monday. Zacks Investment Research raised shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 price objective for the company in a report on Wednesday, July 5th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Agenus in a report on Sunday, April 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Agenus currently has an average rating of “Buy” and a consensus target price of $5.88.

WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/07/26/zacks-brokerages-expect-agenus-inc-agen-will-announce-quarterly-sales-of-6-49-million.html.

Several hedge funds have recently added to or reduced their stakes in the company. American International Group Inc. boosted its stake in Agenus by 7.1% in the first quarter. American International Group Inc. now owns 45,013 shares of the biotechnology company’s stock worth $170,000 after buying an additional 2,984 shares in the last quarter. Quotient Investors LLC boosted its stake in Agenus by 8.8% in the first quarter. Quotient Investors LLC now owns 47,000 shares of the biotechnology company’s stock worth $177,000 after buying an additional 3,800 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in Agenus by 12.2% in the first quarter. Metropolitan Life Insurance Co. NY now owns 55,920 shares of the biotechnology company’s stock worth $211,000 after buying an additional 6,101 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Agenus by 7.8% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 97,342 shares of the biotechnology company’s stock worth $367,000 after buying an additional 7,050 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Agenus by 1.9% in the first quarter. Wells Fargo & Company MN now owns 466,799 shares of the biotechnology company’s stock worth $1,759,000 after buying an additional 8,921 shares in the last quarter. 42.61% of the stock is owned by institutional investors and hedge funds.

Shares of Agenus (AGEN) traded up 1.95% on Wednesday, reaching $5.24. 502,981 shares of the company traded hands. The stock’s market capitalization is $519.38 million. The company has a 50-day moving average of $4.03 and a 200-day moving average of $3.88. Agenus has a 1-year low of $3.20 and a 1-year high of $7.49.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get a free copy of the Zacks research report on Agenus (AGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.